0	0	2000-09-21	CD	O	O	B-Num
0	1	16	CD	O	O	B-Num
0	2	:	:	O	O	I-Num
0	3	42	CD	O	B-NP	I-Num
0	4	WOMEN	NNS	O	I-NP	O
0	5	FINALLY	NNP	O	B-NP	O
0	6	MAKING	VBG	O	B-PP	O
0	7	THE	DT	O	B-NP	O
0	8	CHART	NNP	O	I-NP	B-Org
0	9	FOR	IN	O	B-PP	I-Org
0	10	MEDICAL	NNP	O	B-NP	I-Org
0	11	STUDIES	NNS	O	I-NP	I-Org
0	12	&	CC	O	O	O
0	13	HT	NNP	O	B-NP	O
0	14	;	:	O	O	O

1	0	-LBR-	-LBR-	O	O	O
1	1	UNDATED	NNP	O	O	B-Org
1	2	-RBR-	-RBR-	O	O	O
1	3	The	DT	O	B-NP	O
1	4	early	JJ	O	I-NP	O
1	5	prognosis	NN	O	I-NP	B-Medical
1	6	was	VBD	O	B-VP	O
1	7	grim	JJ	O	O	O
1	8	when	WRB	O	O	O
1	9	Phyllis	NNP	O	B-NP	B-Peop
1	10	DeAngelis	NNP	O	I-NP	I-Peop
1	11	was	VBD	O	B-VP	O
1	12	diagnosed	VBN	O	I-VP	O
1	13	with	IN	O	B-PP	O
1	14	lung	NN	O	B-NP	B-Medical
1	15	cancer	NN	O	I-NP	B-Medical
1	16	six	CD	O	B-NP	B-Num
1	17	years	NNS	O	I-NP	B-Date
1	18	ago	IN	O	O	O
1	19	.	.	O	O	O

2	0	The	DT	O	B-NP	O
2	1	Brick	NNP	O	I-NP	O
2	2	Township	NNP	O	I-NP	O
2	3	COMMA	COMMA	O	O	O
2	4	N.J.	NNP	O	O	B-LocStat
2	5	COMMA	COMMA	O	O	O
2	6	resident	NN	O	B-NP	O
2	7	had	VBD	O	B-VP	O
2	8	a	DT	O	B-NP	O
2	9	Stage	NN	O	I-NP	O
2	10	3	CD	O	I-NP	B-Num
2	11	tumor	NN	O	I-NP	O
2	12	the	DT	O	B-NP	O
2	13	size	NN	O	I-NP	O
2	14	of	IN	O	B-PP	O
2	15	a	DT	O	B-NP	O
2	16	grapefruit	NN	O	I-NP	O
2	17	wrapped	VBN	O	B-VP	O
2	18	around	IN	O	B-PP	O
2	19	her	PP$	O	O	O
2	20	jugular	JJ	O	O	O
2	21	vein	NN	O	O	O
2	22	COMMA	COMMA	O	O	O
2	23	and	CC	O	O	O
2	24	doctors	NNS	O	B-NP	B-ProfTitle
2	25	gave	VBD	O	B-VP	O
2	26	her	PRP	O	B-NP	O
2	27	just	RB	O	O	O
2	28	months	NNS	O	B-NP	B-Date
2	29	to	TO	O	B-VP	O
2	30	live	VB	O	I-VP	O
2	31	.	.	O	O	O

3	0	So	IN	O	O	O
3	1	DeAngelis	NNP	O	B-NP	B-Peop
3	2	COMMA	COMMA	O	O	O
3	3	now	RB	O	O	O
3	4	62	CD	O	B-NP	B-Num
3	5	COMMA	COMMA	O	O	O
3	6	decided	VBD	O	B-VP	O
3	7	to	TO	O	I-VP	O
3	8	participate	VB	O	I-VP	O
3	9	in	IN	O	B-PP	O
3	10	an	DT	O	B-NP	O
3	11	experimental	JJ	O	I-NP	B-Medical
3	12	cancer	NN	O	I-NP	B-Medical
3	13	drug	NN	O	I-NP	I-Medical
3	14	trial	NN	O	I-NP	O
3	15	at	IN	O	B-PP	O
3	16	Fox	NNP	O	B-NP	B-LocStruct
3	17	Chase	NNP	O	I-NP	I-LocStruct
3	18	Cancer	NNP	O	I-NP	I-LocStruct
3	19	Center	NNP	O	I-NP	I-LocStruct
3	20	in	IN	O	B-PP	O
3	21	Philadelphia	NNP	O	B-NP	B-LocCit
3	22	COMMA	COMMA	O	O	O
3	23	where	WRB	O	O	O
3	24	she	PRP	O	B-NP	O
3	25	was	VBD	O	B-VP	O
3	26	given	VBN	O	I-VP	O
3	27	a	DT	O	B-NP	O
3	28	combination	NN	O	I-NP	B-Medical
3	29	of	IN	O	B-PP	O
3	30	Taxol	NNP	O	B-NP	B-Org
3	31	and	CC	O	I-NP	I-Org
3	32	Cisplatin	NNP	O	I-NP	I-Org
3	33	.	.	O	O	O

4	0	``	``	O	O	O
4	1	Taxol	NNP	O	B-NP	B-Peop
4	2	had	VBD	O	B-VP	O
4	3	been	VBN	O	I-VP	O
4	4	used	VBN	O	I-VP	O
4	5	for	IN	O	B-PP	O
4	6	other	JJ	O	B-NP	O
4	7	cancers	NNS	O	I-NP	O
4	8	COMMA	COMMA	O	O	O
4	9	but	CC	O	O	O
4	10	not	RB	O	O	O
4	11	for	IN	O	B-PP	O
4	12	lungCOMMA	NN	O	B-NP	O
4	13	''	''	O	O	O
4	14	she	PRP	O	B-NP	O
4	15	said	VBD	O	B-VP	O
4	16	.	.	O	O	O

5	0	Before	IN	O	B-PP	O
5	1	entering	VBG	O	B-VP	O
5	2	the	DT	O	B-NP	O
5	3	trial	NN	O	I-NP	O
5	4	COMMA	COMMA	O	O	O
5	5	DeAngelis	NNP	O	B-NP	B-Peop
5	6	underwent	VBD	O	B-VP	O
5	7	seven	CD	O	B-NP	B-Num
5	8	weeks	NNS	O	I-NP	O
5	9	of	IN	O	B-PP	O
5	10	radiation	NN	O	B-NP	O
5	11	treatment	NN	O	I-NP	O
5	12	to	TO	O	B-VP	O
5	13	stop	VB	O	I-VP	O
5	14	the	DT	O	B-NP	O
5	15	tumor	NN	O	I-NP	O
5	16	's	POS	O	B-NP	O
5	17	growth	NN	O	I-NP	O
5	18	.	.	O	O	O

6	0	After	IN	O	B-PP	O
6	1	the	DT	O	B-NP	O
6	2	treatment	NN	O	I-NP	O
6	3	ended	VBD	O	B-VP	O
6	4	COMMA	COMMA	O	O	O
6	5	there	EX	O	B-NP	O
6	6	was	VBD	O	B-VP	O
6	7	more	RBR	O	O	O
6	8	bad	JJ	O	B-NP	O
6	9	news	NN	O	I-NP	O
6	10	:	:	O	O	O
6	11	a	DT	O	B-NP	O
6	12	lump	NN	O	I-NP	O
6	13	in	IN	O	B-PP	O
6	14	her	PP$	O	B-NP	O
6	15	neck	NN	O	I-NP	O
6	16	_	NN	O	I-NP	O
6	17	proof	NN	O	I-NP	O
6	18	the	DT	O	B-NP	O
6	19	disease	NN	O	I-NP	B-Medical
6	20	had	VBD	O	B-VP	O
6	21	spread	VBN	O	I-VP	O
6	22	to	TO	O	B-PP	O
6	23	her	PP$	O	B-NP	O
6	24	lymph	NN	O	I-NP	O
6	25	nodes	NNS	O	I-NP	O
6	26	.	.	O	O	O

7	0	By	IN	O	B-PP	O
7	1	the	DT	O	B-NP	O
7	2	time	NN	O	I-NP	O
7	3	she	PRP	O	B-NP	O
7	4	entered	VBD	O	B-VP	O
7	5	the	DT	O	B-NP	O
7	6	trial	NN	O	I-NP	O
7	7	COMMA	COMMA	O	O	O
7	8	doctors	NNS	O	B-NP	B-ProfTitle
7	9	at	IN	O	B-PP	O
7	10	Fox	NNP	O	B-NP	B-Peop
7	11	Chase	NNP	O	I-NP	I-Peop
7	12	thought	VBD	O	B-VP	O
7	13	the	DT	O	B-NP	O
7	14	experimental	JJ	O	I-NP	B-Medical
7	15	drugs	NNS	O	I-NP	O
7	16	would	MD	O	B-VP	O
7	17	prolong	VB	O	I-VP	O
7	18	her	PP$	O	B-NP	O
7	19	life	NN	O	I-NP	O
7	20	for	IN	O	B-PP	O
7	21	only	RB	O	O	O
7	22	a	DT	O	O	O
7	23	month	NN	O	O	O
7	24	_	NN	O	B-VP	O
7	25	maybe	RB	O	B-NP	O
7	26	two	CD	O	I-NP	B-Num
7	27	.	.	O	O	O

8	0	Phyllis	NNP	O	B-NP	B-Peop
8	1	DeAngelis	NNP	O	I-NP	I-Peop
8	2	is	VBZ	O	B-VP	O
8	3	happy	JJ	O	O	O
8	4	to	TO	O	B-VP	O
8	5	say	VB	O	I-VP	O
8	6	she	PRP	O	B-NP	O
8	7	's	VBZ	O	B-VP	O
8	8	still	RB	O	O	O
8	9	here	RB	O	O	O
8	10	and	CC	O	O	O
8	11	has	VBZ	O	B-VP	O
8	12	been	VBN	O	I-VP	O
8	13	cancer-free	NN	O	B-NP	O
8	14	for	IN	O	B-PP	O
8	15	51/2	NN	O	B-NP	B-Num
8	16	years	NNS	O	I-NP	I-Num
8	17	.	.	O	O	O

9	0	``	``	O	O	O
9	1	I	PRP	O	B-NP	O
9	2	'm	VBP	O	B-VP	O
9	3	very	RB	O	O	O
9	4	blessedCOMMA	NN	O	O	O
9	5	''	''	O	O	O
9	6	she	PRP	O	B-NP	O
9	7	said	VBD	O	B-VP	O
9	8	.	.	O	O	O

10	0	DeAngelis	NNP	O	B-NP	B-Peop
10	1	'	POS	O	B-NP	O
10	2	story	NN	O	I-NP	O
10	3	is	VBZ	O	B-VP	O
10	4	an	DT	O	B-NP	O
10	5	example	NN	O	I-NP	O
10	6	of	IN	O	B-PP	O
10	7	what	WP	O	B-NP	O
10	8	is	VBZ	O	B-VP	O
10	9	slowly	RB	O	I-VP	O
10	10	changing	VBG	O	I-VP	O
10	11	from	IN	O	B-PP	O
10	12	a	DT	O	B-NP	O
10	13	rarity	NN	O	I-NP	O
10	14	to	TO	O	B-PP	O
10	15	common	JJ	O	B-NP	O
10	16	practice	NN	O	I-NP	O
10	17	:	:	O	O	O
10	18	women	NNS	O	B-NP	O
10	19	involved	VBD	O	B-VP	O
10	20	in	IN	O	B-PP	O
10	21	clinical	JJ	O	B-NP	B-Medical
10	22	trials	NNS	O	I-NP	O
10	23	.	.	O	O	O

11	0	At	IN	O	B-PP	O
11	1	the	DT	O	B-NP	O
11	2	time	NN	O	I-NP	O
11	3	COMMA	COMMA	O	O	O
11	4	DeAngelis	NNP	O	B-NP	B-Peop
11	5	was	VBD	O	B-VP	O
11	6	the	DT	O	B-NP	O
11	7	only	JJ	O	I-NP	O
11	8	woman	NN	O	I-NP	O
11	9	involved	VBD	O	B-VP	O
11	10	in	IN	O	B-PP	O
11	11	the	DT	O	B-NP	O
11	12	Taxol/Cisplatin	NNP	O	I-NP	O
11	13	drug	NN	O	I-NP	B-Medical
11	14	trial	NN	O	I-NP	O
11	15	COMMA	COMMA	O	O	O
11	16	and	CC	O	O	O
11	17	was	VBD	O	B-VP	O
11	18	one	CD	O	B-NP	B-Num
11	19	of	IN	O	B-PP	O
11	20	its	PP$	O	B-NP	O
11	21	few	JJ	O	I-NP	O
11	22	successes	NNS	O	I-NP	O
11	23	.	.	O	O	O

12	0	Lung	NNP	O	B-NP	O
12	1	cancer	NN	O	I-NP	B-Medical
12	2	patients	NNS	O	I-NP	O
12	3	now	RB	O	O	O
12	4	receive	VBP	O	B-VP	O
12	5	treatments	NNS	O	B-NP	O
12	6	based	VBN	O	B-VP	O
12	7	in	IN	O	B-PP	O
12	8	part	NN	O	B-NP	O
12	9	on	IN	O	B-PP	O
12	10	the	DT	O	B-NP	O
12	11	conclusions	NNS	O	I-NP	O
12	12	drawn	VBN	O	B-VP	O
12	13	from	IN	O	B-PP	O
12	14	that	DT	O	B-NP	O
12	15	trial	NN	O	I-NP	O
12	16	.	.	O	O	O

13	0	Women	NNP	O	B-NP	B-Peop
13	1	's	POS	O	B-NP	O
13	2	participation	NN	O	I-NP	O
13	3	in	IN	O	B-PP	O
13	4	medical	JJ	O	B-NP	O
13	5	research	NN	O	I-NP	O
13	6	and	CC	O	I-NP	O
13	7	clinical	JJ	O	I-NP	B-Medical
13	8	trials	NNS	O	I-NP	O
13	9	was	VBD	O	B-VP	O
13	10	infrequent	JJ	O	O	O
13	11	for	IN	O	B-PP	O
13	12	the	DT	O	B-NP	O
13	13	first	JJ	O	I-NP	B-Num
13	14	20	CD	O	I-NP	B-Num
13	15	years	NNS	O	I-NP	I-Num
13	16	or	CC	O	I-NP	O
13	17	so	RB	O	I-NP	O
13	18	of	IN	O	B-PP	O
13	19	modern	JJ	O	B-NP	O
13	20	research	NN	O	I-NP	O
13	21	.	.	O	O	O

14	0	However	RB	O	O	O
14	1	COMMA	COMMA	O	O	O
14	2	in	IN	O	B-PP	O
14	3	the	DT	O	B-NP	O
14	4	seven	CD	O	I-NP	B-Num
14	5	years	NNS	O	I-NP	B-Date
14	6	since	IN	O	O	O
14	7	federal	JJ	O	B-NP	O
14	8	law	NN	O	I-NP	O
14	9	has	VBZ	O	B-VP	O
14	10	required	VBN	O	I-VP	O
14	11	women	NNS	O	B-NP	O
14	12	's	POS	O	B-NP	O
14	13	inclusion	NN	O	I-NP	O
14	14	in	IN	O	B-PP	O
14	15	studies	NNS	O	B-NP	O
14	16	COMMA	COMMA	O	O	O
14	17	their	PP$	O	B-NP	O
14	18	numbers	NNS	O	I-NP	O
14	19	have	VBP	O	B-VP	O
14	20	increased	VBN	O	I-VP	O
14	21	.	.	O	O	O

15	0	Women	NNP	O	B-NP	B-Peop
15	1	initially	RB	O	O	O
15	2	were	VBD	O	B-VP	O
15	3	excluded	VBN	O	I-VP	O
15	4	from	IN	O	B-PP	O
15	5	much	JJ	O	B-NP	O
15	6	of	IN	O	B-PP	O
15	7	the	DT	O	B-NP	O
15	8	research	NN	O	I-NP	O
15	9	because	IN	O	O	O
15	10	COMMA	COMMA	O	O	O
15	11	among	IN	O	B-PP	O
15	12	other	JJ	O	B-NP	O
15	13	reasons	NNS	O	I-NP	O
15	14	COMMA	COMMA	O	O	O
15	15	they	PRP	O	B-NP	O
15	16	presented	VBD	O	B-VP	O
15	17	too	RB	O	B-NP	O
15	18	many	JJ	O	I-NP	O
15	19	biological	JJ	O	I-NP	B-Medical
15	20	variables	NNS	O	I-NP	O
15	21	_	NN	O	I-NP	O
15	22	such	JJ	O	B-PP	O
15	23	as	IN	O	I-PP	O
15	24	risk	NN	O	B-NP	O
15	25	of	IN	O	B-PP	O
15	26	pregnancy	NN	O	B-NP	B-Medical
15	27	.	.	O	O	O

16	0	Legislation	NN	O	B-NP	O
16	1	that	WDT	O	B-NP	O
16	2	would	MD	O	B-VP	O
16	3	have	VB	O	I-VP	O
16	4	required	VBN	O	I-VP	O
16	5	inclusion	NN	O	O	O
16	6	of	IN	O	B-PP	O
16	7	women	NNS	O	B-NP	O
16	8	and	CC	O	I-NP	O
16	9	minorities	NNS	O	I-NP	O
16	10	in	IN	O	B-PP	O
16	11	studies	NNS	O	B-NP	O
16	12	was	VBD	O	B-VP	O
16	13	introduced	VBN	O	I-VP	O
16	14	in	IN	O	B-PP	O
16	15	Congress	NNP	O	B-NP	B-OrgPolBody
16	16	in	IN	O	B-PP	O
16	17	1990	CD	O	B-NP	B-Date
16	18	.	.	O	O	O

17	0	But	CC	O	O	O
17	1	it	PRP	O	B-NP	O
17	2	wasn	NN	O	B-NP	O
17	3	't	NN	O	I-NP	O
17	4	until	IN	O	B-PP	O
17	5	three	CD	O	B-NP	B-Num
17	6	years	NNS	O	I-NP	B-Date
17	7	later	RB	O	O	O
17	8	that	IN	O	O	O
17	9	President	NNP	O	B-NP	B-ProfTitle
17	10	Clinton	NNP	O	I-NP	B-Peop
17	11	signed	VBD	O	B-VP	O
17	12	a	DT	O	B-NP	O
17	13	bill	NN	O	I-NP	O
17	14	mandating	VBG	O	B-VP	O
17	15	that	DT	O	B-NP	O
17	16	research	NN	O	I-NP	O
17	17	funded	VBN	O	B-VP	O
17	18	by	IN	O	B-PP	O
17	19	the	DT	O	B-NP	O
17	20	National	NNP	O	I-NP	B-Org
17	21	Institutes	NNPS	O	I-NP	I-Org
17	22	of	IN	O	B-PP	O
17	23	Health	NNP	O	B-NP	O
17	24	include	VBP	O	B-VP	O
17	25	men	NNS	O	B-NP	O
17	26	and	CC	O	I-NP	O
17	27	women	NNS	O	I-NP	O
17	28	.	.	O	O	O

18	0	Statistics	NNP	O	B-NP	O
18	1	from	IN	O	B-PP	O
18	2	1998	CD	O	B-NP	B-Date
18	3	-LBR-	-LBR-	O	O	O
18	4	the	DT	O	B-NP	O
18	5	latest	JJS	O	I-NP	O
18	6	year	NN	O	I-NP	O
18	7	available	JJ	O	O	O
18	8	-RBR-	-RBR-	O	O	O
18	9	show	VBP	O	B-VP	O
18	10	that	IN	O	O	O
18	11	more	JJR	O	O	O
18	12	than	IN	O	B-PP	O
18	13	65	CD	O	B-NP	B-NumPercent
18	14	percent	NN	O	I-NP	I-NumPercent
18	15	of	IN	O	B-PP	O
18	16	participants	NNS	O	B-NP	O
18	17	in	IN	O	B-PP	O
18	18	NIH	NNP	O	B-NP	B-Loc
18	19	studies	NNS	O	I-NP	O
18	20	were	VBD	O	B-VP	O
18	21	women	NNS	O	B-NP	O
18	22	.	.	O	O	O

19	0	Of	IN	O	B-PP	O
19	1	6COMMA947	CD	O	B-NP	B-Num
19	2	studies	NNS	O	I-NP	O
19	3	supported	VBN	O	B-VP	O
19	4	by	IN	O	B-PP	O
19	5	NIH	NNP	O	B-NP	O
19	6	that	DT	O	B-NP	O
19	7	year	NN	O	I-NP	O
19	8	COMMA	COMMA	O	O	O
19	9	6COMMA000	CD	O	B-NP	B-Num
19	10	included	VBD	O	B-VP	O
19	11	men	NNS	O	B-NP	O
19	12	and	CC	O	I-NP	O
19	13	women	NNS	O	I-NP	O
19	14	.	.	O	O	O

20	0	Fewer	JJR	O	B-NP	O
20	1	than	IN	O	I-NP	O
20	2	250	CD	O	I-NP	B-Num
20	3	studies	NNS	O	I-NP	O
20	4	were	VBD	O	B-VP	O
20	5	designed	VBN	O	I-VP	O
20	6	for	IN	O	B-PP	O
20	7	men	NNS	O	B-NP	O
20	8	only	RB	O	O	O
20	9	COMMA	COMMA	O	O	O
20	10	and	CC	O	O	O
20	11	about	IN	O	O	O
20	12	740	CD	O	O	B-Num
20	13	studies	NNS	O	B-NP	O
20	14	were	VBD	O	B-VP	O
20	15	limited	JJ	O	O	O
20	16	to	TO	O	B-PP	O
20	17	women	NNS	O	B-NP	O
20	18	.	.	O	O	O

21	0	Ray	NNP	O	B-NP	B-Peop
21	1	Woosley	NNP	O	I-NP	I-Peop
21	2	COMMA	COMMA	O	O	O
21	3	head	NN	O	B-NP	O
21	4	of	IN	O	B-PP	O
21	5	the	DT	O	B-NP	O
21	6	pharmacology	NN	O	I-NP	O
21	7	department	NN	O	I-NP	O
21	8	at	IN	O	B-PP	O
21	9	Georgetown	NNP	O	B-NP	B-OrgUniv
21	10	University	NNP	O	I-NP	I-OrgUniv
21	11	and	CC	O	O	O
21	12	a	DT	O	B-NP	O
21	13	director	NN	O	I-NP	B-ProfTitle
21	14	of	IN	O	B-PP	O
21	15	clinical	JJ	O	B-NP	B-Medical
21	16	research	NN	O	I-NP	O
21	17	COMMA	COMMA	O	O	O
21	18	said	VBD	O	B-VP	O
21	19	anecdotal	JJ	O	B-NP	O
21	20	evidence	NN	O	I-NP	O
21	21	shows	VBZ	O	B-VP	O
21	22	that	IN	O	O	O
21	23	women	NNS	O	B-NP	O
21	24	are	VBP	O	B-VP	O
21	25	affected	VBN	O	I-VP	O
21	26	by	IN	O	B-PP	O
21	27	drugs	NNS	O	B-NP	O
21	28	differently	RB	O	O	O
21	29	than	IN	O	B-PP	O
21	30	men	NNS	O	B-NP	O
21	31	.	.	O	O	O

22	0	For	IN	O	B-PP	O
22	1	example	NN	O	B-NP	O
22	2	COMMA	COMMA	O	O	O
22	3	women	NNS	O	B-NP	O
22	4	have	VBP	O	B-VP	O
22	5	different	JJ	O	B-NP	O
22	6	drug	NN	O	I-NP	B-Medical
22	7	sensitivities	NNS	O	I-NP	O
22	8	depending	VBG	O	B-VP	O
22	9	on	IN	O	B-PP	O
22	10	which	WDT	O	B-NP	O
22	11	phase	NN	O	I-NP	O
22	12	of	IN	O	B-PP	O
22	13	their	PP$	O	B-NP	O
22	14	menstrual	JJ	O	I-NP	O
22	15	cycle	NN	O	I-NP	B-Medical
22	16	they	PRP	O	B-NP	O
22	17	are	VBP	O	B-VP	O
22	18	in	IN	O	B-PP	O
22	19	.	.	O	O	O

23	0	Seldane	NNP	O	B-NP	B-Peop
23	1	COMMA	COMMA	O	O	O
23	2	an	DT	O	B-NP	O
23	3	allergy	NN	O	I-NP	B-Medical
23	4	drug	NN	O	I-NP	I-Medical
23	5	COMMA	COMMA	O	O	O
23	6	and	CC	O	O	O
23	7	Propulsid	NNP	O	B-NP	B-Peop
23	8	COMMA	COMMA	O	O	O
23	9	a	DT	O	B-NP	O
23	10	drug	NN	O	I-NP	B-Medical
23	11	for	IN	O	B-PP	O
23	12	gastrointestinal	JJ	O	B-NP	B-Medical
23	13	complaints	NNS	O	I-NP	O
23	14	COMMA	COMMA	O	O	O
23	15	were	VBD	O	B-VP	O
23	16	taken	VBN	O	I-VP	O
23	17	off	IN	O	B-PP	O
23	18	the	DT	O	B-NP	O
23	19	market	NN	O	I-NP	O
23	20	because	IN	O	B-PP	O
23	21	of	IN	O	I-PP	O
23	22	adverse	JJ	O	B-NP	B-Medical
23	23	side	NN	O	I-NP	O
23	24	effects	NNS	O	I-NP	O
23	25	like	VBP	O	B-VP	O
23	26	heart	NN	O	B-NP	B-Medical
23	27	arrhythmia	NN	O	I-NP	B-Medical
23	28	.	.	O	O	O

24	0	The	DT	O	B-NP	O
24	1	majority	NN	O	I-NP	O
24	2	of	IN	O	B-PP	O
24	3	those	DT	O	B-NP	O
24	4	reporting	VBG	O	B-VP	O
24	5	the	DT	O	B-NP	O
24	6	adverse	JJ	O	I-NP	B-Medical
24	7	effects	NNS	O	I-NP	O
24	8	were	VBD	O	B-VP	O
24	9	women	NNS	O	B-NP	O
24	10	.	.	O	O	O

25	0	``	``	O	O	O
25	1	Women	NNS	O	B-NP	O
25	2	are	VBP	O	B-VP	O
25	3	more	RBR	O	O	O
25	4	variable	NN	O	O	O
25	5	than	IN	O	B-PP	O
25	6	menCOMMA	NN	O	B-NP	O
25	7	''	''	O	O	O
25	8	Woosley	NNP	O	B-NP	B-Peop
25	9	said	VBD	O	B-VP	O
25	10	.	.	O	O	O

26	0	``	``	O	O	O
26	1	The	DT	O	B-NP	O
26	2	more	JJR	O	I-NP	O
26	3	variability	NN	O	I-NP	O
26	4	you	PRP	O	B-NP	O
26	5	have	VBP	O	B-VP	O
26	6	in	IN	O	B-PP	O
26	7	a	DT	O	B-NP	O
26	8	study	NN	O	I-NP	O
26	9	COMMA	COMMA	O	O	O
26	10	the	DT	O	O	O
26	11	more	RBR	O	O	O
26	12	difficult	JJ	O	O	O
26	13	it	PRP	O	B-NP	O
26	14	is	VBZ	O	B-VP	O
26	15	to	TO	O	B-VP	O
26	16	prove	VB	O	I-VP	O
26	17	your	PP$	O	B-NP	O
26	18	premise	NN	O	I-NP	O
26	19	.	.	O	O	O

27	0	By	IN	O	B-PP	O
27	1	picking	VBG	O	B-VP	O
27	2	all	DT	O	B-NP	O
27	3	male	JJ	O	I-NP	O
27	4	rats	NNS	O	I-NP	B-Animal
27	5	for	IN	O	B-PP	O
27	6	a	DT	O	B-NP	O
27	7	study	NN	O	I-NP	O
27	8	COMMA	COMMA	O	O	O
27	9	you	PRP	O	B-NP	O
27	10	filter	NN	O	B-NP	O
27	11	down	IN	O	O	O
27	12	to	TO	O	B-PP	O
27	13	a	DT	O	B-NP	O
27	14	very	RB	O	I-NP	O
27	15	homogeneous	JJ	O	I-NP	B-Medical
27	16	group	NN	O	I-NP	B-OrgCorp
27	17	.	.	O	O	O

28	0	You	PRP	O	B-NP	O
28	1	throw	VBP	O	B-VP	O
28	2	in	IN	O	B-PP	O
28	3	female	JJ	O	B-NP	O
28	4	rats	NNS	O	I-NP	B-Animal
28	5	COMMA	COMMA	O	O	O
28	6	you	PRP	O	B-NP	O
28	7	have	VBP	O	B-VP	O
28	8	to	TO	O	I-VP	O
28	9	do	VB	O	I-VP	O
28	10	twice	RB	O	O	O
28	11	as	IN	O	O	O
28	12	much	JJ	O	B-NP	O
28	13	work	NN	O	I-NP	O
28	14	.	.	O	O	O
28	15	''	''	O	O	O

29	0	For	IN	O	B-PP	O
29	1	a	DT	O	B-NP	O
29	2	long	JJ	O	I-NP	O
29	3	time	NN	O	I-NP	O
29	4	COMMA	COMMA	O	O	O
29	5	Woosley	NNP	O	B-NP	B-Peop
29	6	said	VBD	O	B-VP	O
29	7	COMMA	COMMA	O	O	O
29	8	a	DT	O	B-NP	O
29	9	lot	NN	O	I-NP	O
29	10	of	IN	O	B-PP	O
29	11	clinical	JJ	O	B-NP	B-Medical
29	12	trials	NNS	O	I-NP	O
29	13	were	VBD	O	B-VP	O
29	14	conducted	VBN	O	I-VP	O
29	15	in	IN	O	B-PP	O
29	16	Veterans	NNP	O	B-NP	B-Loc
29	17	Administration	NNP	O	I-NP	I-Loc
29	18	hospitals	NNS	O	I-NP	O
29	19	because	IN	O	O	O
29	20	the	DT	O	B-NP	O
29	21	population	NN	O	I-NP	O
29	22	was	VBD	O	B-VP	O
29	23	easy	JJ	O	O	O
29	24	to	TO	O	B-VP	O
29	25	monitor	VB	O	I-VP	O
29	26	and	CC	O	O	O
29	27	accessible	JJ	O	O	O
29	28	.	.	O	O	O

30	0	If	IN	O	O	O
30	1	you	PRP	O	B-NP	O
30	2	look	VBP	O	B-VP	O
30	3	at	IN	O	B-PP	O
30	4	mixed-gender	JJ	O	B-NP	O
30	5	trials	NNS	O	I-NP	O
30	6	for	IN	O	B-PP	O
30	7	congestive	JJ	O	B-NP	O
30	8	heart	NN	O	I-NP	B-Medical
30	9	failure	NN	O	I-NP	I-Medical
30	10	COMMA	COMMA	O	O	O
30	11	women	NNS	O	B-NP	O
30	12	are	VBP	O	B-VP	O
30	13	still	RB	O	I-VP	O
30	14	underrepresented	VBN	O	I-VP	O
30	15	.	.	O	O	O

31	0	``	``	O	O	O
31	1	We	PRP	O	B-NP	O
31	2	're	VBP	O	B-VP	O
31	3	doing	VBG	O	I-VP	O
31	4	better	JJR	O	O	O
31	5	COMMA	COMMA	O	O	O
31	6	but	CC	O	O	O
31	7	there	EX	O	B-NP	O
31	8	is	VBZ	O	B-VP	O
31	9	still	RB	O	O	O
31	10	more	JJR	O	O	O
31	11	to	TO	O	B-VP	O
31	12	be	VB	O	I-VP	O
31	13	doneCOMMA	NN	O	O	O
31	14	''	''	O	O	O
31	15	Woosley	NNP	O	B-NP	B-Peop
31	16	said	VBD	O	B-VP	O
31	17	.	.	O	O	O

32	0	Clinical	NNP	O	B-NP	O
32	1	trials	NNS	O	I-NP	O
32	2	can	MD	O	B-VP	O
32	3	be	VB	O	I-VP	O
32	4	tests	NNS	O	B-NP	O
32	5	of	IN	O	B-PP	O
32	6	new	JJ	O	B-NP	O
32	7	medications	NNS	O	I-NP	O
32	8	.	.	O	O	O

33	0	They	PRP	O	B-NP	O
33	1	also	RB	O	O	O
33	2	can	MD	O	B-VP	O
33	3	involve	VB	O	I-VP	O
33	4	lifestyle	NN	O	B-NP	O
33	5	changes	NNS	O	I-NP	O
33	6	and	CC	O	O	O
33	7	behavior	NN	O	B-NP	O
33	8	modification	NN	O	I-NP	O
33	9	to	TO	O	B-VP	O
33	10	see	VB	O	I-VP	O
33	11	if	IN	O	O	O
33	12	those	DT	O	B-NP	O
33	13	changes	NNS	O	I-NP	O
33	14	can	MD	O	B-VP	O
33	15	reduce	VB	O	I-VP	O
33	16	the	DT	O	B-NP	O
33	17	risks	NNS	O	I-NP	O
33	18	of	IN	O	B-PP	O
33	19	certain	JJ	O	B-NP	O
33	20	conditions	NNS	O	I-NP	O
33	21	and	CC	O	I-NP	O
33	22	diseases	NNS	O	I-NP	O
33	23	COMMA	COMMA	O	O	O
33	24	such	JJ	O	B-PP	O
33	25	as	IN	O	I-PP	O
33	26	diabetes	NN	O	B-NP	B-Medical
33	27	and	CC	O	I-NP	O
33	28	osteoporosis	NN	O	I-NP	B-Medical
33	29	.	.	O	O	O

34	0	In	IN	O	B-PP	O
34	1	addition	NN	O	B-NP	O
34	2	to	TO	O	B-PP	O
34	3	Woosley	NNP	O	B-NP	B-Peop
34	4	's	POS	O	B-NP	O
34	5	findings	NNS	O	I-NP	O
34	6	COMMA	COMMA	O	O	O
34	7	there	EX	O	B-NP	O
34	8	is	VBZ	O	B-VP	O
34	9	other	JJ	O	B-NP	O
34	10	evidence	NN	O	I-NP	O
34	11	that	IN	O	O	O
34	12	women	NNS	O	B-NP	O
34	13	have	VBP	O	B-VP	O
34	14	different	JJ	O	B-NP	O
34	15	reactions	NNS	O	I-NP	O
34	16	to	TO	O	B-PP	O
34	17	drugs	NNS	O	B-NP	O
34	18	than	IN	O	B-PP	O
34	19	men	NNS	O	B-NP	O
34	20	.	.	O	O	O

35	0	Antihistamines	NNS	O	O	O
35	1	COMMA	COMMA	O	O	O
35	2	antibiotics	NNS	O	B-NP	O
35	3	and	CC	O	I-NP	O
35	4	pain	NN	O	I-NP	O
35	5	medications	NNS	O	I-NP	O
35	6	cause	VBP	O	B-VP	O
35	7	different	JJ	O	B-NP	O
35	8	reactions	NNS	O	I-NP	O
35	9	and	CC	O	I-NP	O
35	10	side	NN	O	I-NP	O
35	11	effects	NNS	O	I-NP	O
35	12	in	IN	O	B-PP	O
35	13	men	NNS	O	B-NP	O
35	14	and	CC	O	I-NP	O
35	15	women	NNS	O	I-NP	O
35	16	.	.	O	O	O

36	0	One	CD	O	B-NP	B-Num
36	1	study	NN	O	I-NP	O
36	2	found	VBD	O	B-VP	O
36	3	that	IN	O	O	O
36	4	the	DT	O	B-NP	O
36	5	class	NN	O	I-NP	O
36	6	of	IN	O	B-PP	O
36	7	painkillers	NNS	O	B-NP	O
36	8	called	VBN	O	B-VP	O
36	9	kappa	NN	O	B-NP	O
36	10	opioids	NNS	O	I-NP	O
36	11	_	NN	O	I-NP	O
36	12	all	DT	O	B-VP	O
36	13	but	CC	O	I-VP	O
36	14	ignored	VBD	O	I-VP	O
36	15	because	IN	O	O	O
36	16	they	PRP	O	B-NP	O
36	17	showed	VBD	O	B-VP	O
36	18	few	JJ	O	B-NP	O
36	19	benefits	NNS	O	I-NP	O
36	20	in	IN	O	B-PP	O
36	21	men	NNS	O	B-NP	O
36	22	_	NN	O	B-NP	O
36	23	are	VBP	O	B-VP	O
36	24	quite	RB	O	O	O
36	25	effective	JJ	O	O	O
36	26	in	IN	O	B-PP	O
36	27	women	NNS	O	B-NP	O
36	28	.	.	O	O	O

37	0	The	DT	O	B-NP	O
37	1	same	JJ	O	I-NP	O
37	2	is	VBZ	O	B-VP	O
37	3	true	JJ	O	O	O
37	4	of	IN	O	B-PP	O
37	5	a	DT	O	B-NP	O
37	6	new	JJ	O	I-NP	O
37	7	drug	NN	O	I-NP	B-Medical
37	8	for	IN	O	B-PP	O
37	9	irritable	JJ	O	B-NP	O
37	10	bowel	NN	O	I-NP	O
37	11	syndrome	NN	O	I-NP	B-Medical
37	12	COMMA	COMMA	O	O	O
37	13	Lotronex	NNP	O	B-NP	O
37	14	COMMA	COMMA	O	O	O
37	15	which	WDT	O	B-NP	O
37	16	has	VBZ	O	B-VP	O
37	17	been	VBN	O	I-VP	O
37	18	very	RB	O	O	O
37	19	effective	JJ	O	O	O
37	20	in	IN	O	B-PP	O
37	21	women	NNS	O	B-NP	O
37	22	although	IN	O	O	O
37	23	there	EX	O	B-NP	O
37	24	have	VBP	O	B-VP	O
37	25	been	VBN	O	I-VP	O
37	26	reports	NNS	O	B-NP	O
37	27	of	IN	O	B-PP	O
37	28	serious	JJ	O	B-NP	O
37	29	side	NN	O	I-NP	O
37	30	effects	NNS	O	I-NP	O
37	31	.	.	O	O	O

38	0	``	``	O	O	O
38	1	For	IN	O	B-PP	O
38	2	a	DT	O	B-NP	O
38	3	long	JJ	O	I-NP	O
38	4	time	NN	O	I-NP	O
38	5	COMMA	COMMA	O	O	O
38	6	women	NNS	O	B-NP	O
38	7	were	VBD	O	B-VP	O
38	8	pretty	RB	O	O	O
38	9	much	RB	O	O	O
38	10	excluded	VBD	O	B-VP	O
38	11	from	IN	O	B-PP	O
38	12	trials	NNS	O	B-NP	O
38	13	because	IN	O	O	O
38	14	their	PP$	O	B-NP	O
38	15	participation	NN	O	I-NP	O
38	16	would	MD	O	B-VP	O
38	17	change	VB	O	I-VP	O
38	18	the	DT	O	B-NP	O
38	19	resultsCOMMA	NN	O	I-NP	O
38	20	''	''	O	O	O
38	21	said	VBD	O	B-VP	O
38	22	Sebastian	NNP	O	B-NP	B-Peop
38	23	Palmeri	NNP	O	I-NP	I-Peop
38	24	COMMA	COMMA	O	O	O
38	25	associate	VBP	O	O	B-ProfTitle
38	26	professor	NN	O	B-NP	B-ProfTitle
38	27	of	IN	O	B-PP	O
38	28	medicine	NN	O	B-NP	B-Medical
38	29	and	CC	O	O	O
38	30	medical	JJ	O	B-NP	O
38	31	director	NN	O	I-NP	B-ProfTitle
38	32	of	IN	O	B-PP	O
38	33	the	DT	O	B-NP	O
38	34	coronary	JJ	O	I-NP	B-Medical
38	35	care	NN	O	I-NP	O
38	36	unit	NN	O	I-NP	O
38	37	at	IN	O	B-PP	O
38	38	Robert	NNP	O	B-NP	O
38	39	Wood	NNP	O	I-NP	O
38	40	Johnson	NNP	O	I-NP	O
38	41	University	NNP	O	I-NP	B-OrgUniv
38	42	Hospital	NNP	O	I-NP	O
38	43	in	IN	O	B-PP	O
38	44	New	NNP	O	B-NP	B-LocStat
38	45	Brunswick	NNP	O	I-NP	I-LocStat
38	46	COMMA	COMMA	O	O	O
38	47	N.J	NNP	O	B-NP	B-Loc
38	48	.	.	O	O	O

39	0	``	``	O	O	O
39	1	You	PRP	O	B-NP	O
39	2	never	RB	O	O	O
39	3	wanted	VBD	O	B-VP	O
39	4	women	NNS	O	B-NP	O
39	5	of	IN	O	B-PP	O
39	6	child-bearing	JJ	O	B-NP	O
39	7	age	NN	O	I-NP	O
39	8	in	IN	O	B-PP	O
39	9	a	DT	O	B-NP	O
39	10	trial	NN	O	I-NP	O
39	11	because	IN	O	O	O
39	12	there	EX	O	B-NP	O
39	13	could	MD	O	B-VP	O
39	14	be	VB	O	I-VP	O
39	15	some	DT	O	B-NP	O
39	16	unknown	JJ	O	I-NP	O
39	17	risk	NN	O	I-NP	O
39	18	for	IN	O	B-PP	O
39	19	future	JJ	O	B-NP	O
39	20	pregnancies	NNS	O	I-NP	O
39	21	.	.	O	O	O

40	0	Also	RB	O	O	O
40	1	COMMA	COMMA	O	O	O
40	2	women	NNS	O	B-NP	O
40	3	who	WP	O	B-NP	O
40	4	were	VBD	O	B-VP	O
40	5	older	JJR	O	O	O
40	6	and	CC	O	O	O
40	7	more	JJR	O	O	O
40	8	at	IN	O	B-PP	O
40	9	risk	VBP	O	B-NP	O
40	10	for	IN	O	B-PP	O
40	11	heart	NN	O	B-NP	B-Medical
40	12	attack	NN	O	I-NP	I-Medical
40	13	were	VBD	O	B-VP	O
40	14	perceived	VBN	O	I-VP	O
40	15	as	IN	O	B-PP	O
40	16	being	VBG	O	B-VP	O
40	17	more	JJR	O	B-NP	O
40	18	fragileCOMMA	NN	O	I-NP	O
40	19	''	''	O	O	O
40	20	he	PRP	O	B-NP	O
40	21	said	VBD	O	B-VP	O
40	22	.	.	O	O	O

41	0	``	``	O	O	O
41	1	For	IN	O	B-PP	O
41	2	the	DT	O	B-NP	O
41	3	last	JJ	O	I-NP	O
41	4	10	CD	O	I-NP	B-Num
41	5	years	NNS	O	I-NP	I-Num
41	6	COMMA	COMMA	O	O	O
41	7	if	IN	O	O	O
41	8	you	PRP	O	B-NP	O
41	9	put	VBD	O	B-VP	O
41	10	together	RB	O	O	O
41	11	a	DT	O	B-NP	O
41	12	proposal	NN	O	I-NP	O
41	13	for	IN	O	B-PP	O
41	14	NIH	NNP	O	B-NP	B-Org
41	15	funding	NN	O	I-NP	O
41	16	COMMA	COMMA	O	O	O
41	17	you	PRP	O	B-NP	O
41	18	have	VBP	O	B-VP	O
41	19	to	TO	O	I-VP	O
41	20	say	VB	O	I-VP	O
41	21	it	PRP	O	B-NP	O
41	22	's	VBZ	O	B-VP	O
41	23	open	NN	O	B-NP	O
41	24	to	TO	O	B-PP	O
41	25	all	DT	O	B-NP	O
41	26	genders	NNS	O	I-NP	O
41	27	and	CC	O	O	O
41	28	ethnic	JJ	O	B-NP	O
41	29	groups	NNS	O	I-NP	B-OrgCorp
41	30	.	.	O	O	O

42	0	If	IN	O	O	O
42	1	not	RB	O	O	O
42	2	COMMA	COMMA	O	O	O
42	3	you	PRP	O	B-NP	O
42	4	have	VBP	O	B-VP	O
42	5	to	TO	O	I-VP	O
42	6	explain	VB	O	I-VP	O
42	7	why	WRB	O	O	O
42	8	.	.	O	O	O

43	0	This	DT	O	B-NP	O
43	1	gives	VBZ	O	B-VP	O
43	2	you	PRP	O	B-NP	O
43	3	good	RB	O	O	O
43	4	cause	NN	O	B-NP	O
43	5	to	TO	O	B-VP	O
43	6	approach	VB	O	I-VP	O
43	7	patients	NNS	O	B-NP	O
43	8	young	JJ	O	O	O
43	9	and	CC	O	O	O
43	10	old	JJ	O	O	O
43	11	COMMA	COMMA	O	O	O
43	12	male	JJ	O	O	O
43	13	and	CC	O	O	O
43	14	female	JJ	O	O	O
43	15	COMMA	COMMA	O	O	O
43	16	and	CC	O	B-PP	O
43	17	of	IN	O	B-PP	O
43	18	all	DT	O	B-NP	O
43	19	ethnic	JJ	O	I-NP	O
43	20	groups	NNS	O	I-NP	B-OrgCorp
43	21	.	.	O	O	O

44	0	But	CC	O	O	O
44	1	some	DT	O	B-NP	O
44	2	studies	NNS	O	I-NP	O
44	3	are	VBP	O	B-VP	O
44	4	still	RB	O	O	O
44	5	weighted	JJ	O	O	O
44	6	disproportionately	RB	O	O	O
44	7	to	TO	O	B-PP	O
44	8	middle-aged	JJ	O	B-NP	O
44	9	white	JJ	O	I-NP	B-Color
44	10	males	NNS	O	I-NP	O
44	11	.	.	O	O	O
44	12	''	''	O	O	O

45	0	However	RB	O	O	O
45	1	COMMA	COMMA	O	O	O
45	2	there	EX	O	B-NP	O
45	3	are	VBP	O	B-VP	O
45	4	some	DT	O	B-NP	O
45	5	important	JJ	O	I-NP	O
45	6	gender-specific	JJ	O	I-NP	O
45	7	studies	NNS	O	I-NP	O
45	8	being	VBG	O	B-VP	O
45	9	conducted	VBN	O	I-VP	O
45	10	today	NN	O	B-NP	B-Date
45	11	.	.	O	O	O

46	0	There	EX	O	B-NP	O
46	1	is	VBZ	O	B-VP	O
46	2	a	DT	O	B-NP	O
46	3	large	JJ	O	I-NP	O
46	4	national	JJ	O	I-NP	O
46	5	trial	NN	O	I-NP	O
46	6	involving	VBG	O	B-VP	O
46	7	161COMMA000	CD	O	B-NP	B-Num
46	8	women	NNS	O	I-NP	O
46	9	to	TO	O	B-VP	O
46	10	determine	VB	O	I-VP	O
46	11	the	DT	O	B-NP	O
46	12	effects	NNS	O	I-NP	O
46	13	of	IN	O	B-PP	O
46	14	calcium	NN	O	B-NP	O
46	15	supplements	NNS	O	I-NP	O
46	16	and	CC	O	I-NP	O
46	17	hormone	NN	O	I-NP	B-Medical
46	18	replacement	NN	O	I-NP	O
46	19	on	IN	O	B-PP	O
46	20	postmenopausal	NN	O	B-NP	B-Medical
46	21	women	NNS	O	I-NP	O
46	22	.	.	O	O	O

47	0	About	IN	O	B-NP	O
47	1	900	CD	O	I-NP	B-Num
47	2	women	NNS	O	I-NP	O
47	3	also	RB	O	O	O
47	4	are	VBP	O	B-VP	O
47	5	being	VBG	O	I-VP	O
47	6	studied	VBN	O	I-VP	O
47	7	for	IN	O	B-PP	O
47	8	a	DT	O	B-NP	O
47	9	type	NN	O	I-NP	O
47	10	of	IN	O	B-PP	O
47	11	heart	NN	O	B-NP	B-Medical
47	12	disease	NN	O	I-NP	I-Medical
47	13	.	.	O	O	O

48	0	&	CC	O	O	O
48	1	UR	NNP	O	B-NP	O
48	2	;	:	O	O	O
48	3	-LBR-	-LBR-	O	O	O
48	4	OPTIONAL	NNP	O	O	O
48	5	TRIM	NNP	O	O	O
48	6	FOLLOWS	NNP	O	O	O
48	7	-RBR-	-RBR-	O	O	O
48	8	&	CC	O	O	O
48	9	LR	NNP	O	B-NP	O
48	10	;	:	O	O	O

49	0	After	IN	O	B-PP	O
49	1	heart	NN	O	B-NP	B-Medical
49	2	disease	NN	O	I-NP	I-Medical
49	3	COMMA	COMMA	O	O	O
49	4	stroke	NN	O	O	B-Medical
49	5	and	CC	O	O	O
49	6	lung	NN	O	B-NP	B-Medical
49	7	cancer	NN	O	I-NP	B-Medical
49	8	and	CC	O	O	O
49	9	other	JJ	O	B-NP	O
49	10	lung	NN	O	I-NP	B-Medical
49	11	conditions	NNS	O	I-NP	O
49	12	COMMA	COMMA	O	O	O
49	13	such	JJ	O	B-PP	O
49	14	as	IN	O	I-PP	O
49	15	emphysema	NN	O	B-NP	B-Medical
49	16	COMMA	COMMA	O	O	O
49	17	are	VBP	O	B-VP	O
49	18	the	DT	O	B-NP	O
49	19	leading	VBG	O	I-NP	O
49	20	causes	NNS	O	I-NP	O
49	21	of	IN	O	B-PP	O
49	22	death	NN	O	B-NP	O
49	23	for	IN	O	B-PP	O
49	24	women	NNS	O	B-NP	O
49	25	.	.	O	O	O

50	0	But	CC	O	O	O
50	1	breast	NN	O	B-NP	O
50	2	cancer	NN	O	I-NP	B-Medical
50	3	COMMA	COMMA	O	O	O
50	4	which	WDT	O	B-NP	O
50	5	is	VBZ	O	B-VP	O
50	6	the	DT	O	B-NP	O
50	7	cause	NN	O	I-NP	O
50	8	of	IN	O	B-PP	O
50	9	death	NN	O	B-NP	O
50	10	for	IN	O	B-PP	O
50	11	only	RB	O	B-NP	O
50	12	4	CD	O	I-NP	B-NumPercent
50	13	percent	NN	O	I-NP	I-NumPercent
50	14	of	IN	O	B-PP	O
50	15	women	NNS	O	B-NP	O
50	16	in	IN	O	B-PP	O
50	17	the	DT	O	B-NP	O
50	18	United	NNP	O	I-NP	B-LocCoun
50	19	States	NNPS	O	I-NP	I-LocCoun
50	20	COMMA	COMMA	O	O	O
50	21	has	VBZ	O	B-VP	O
50	22	a	DT	O	B-NP	O
50	23	much	RB	O	I-NP	O
50	24	higher	JJR	O	I-NP	O
50	25	profile	NN	O	I-NP	O
50	26	.	.	O	O	O

51	0	``	``	O	O	O
51	1	Breast	NNP	O	B-NP	O
51	2	cancer	NN	O	I-NP	B-Medical
51	3	kills	VBZ	O	B-VP	O
51	4	4	CD	O	B-NP	B-NumPercent
51	5	percent	NN	O	I-NP	I-NumPercent
51	6	of	IN	O	B-PP	O
51	7	women	NNS	O	B-NP	O
51	8	COMMA	COMMA	O	O	O
51	9	but	CC	O	O	O
51	10	all	PDT	O	B-NP	O
51	11	the	DT	O	I-NP	O
51	12	research	NN	O	I-NP	O
51	13	and	CC	O	I-NP	O
51	14	outreach	NN	O	I-NP	O
51	15	has	VBZ	O	B-VP	O
51	16	made	VBN	O	I-VP	O
51	17	it	PRP	O	B-NP	O
51	18	more	RBR	O	O	O
51	19	noticeable	JJ	O	O	O
51	20	than	IN	O	B-PP	O
51	21	heart	NN	O	B-NP	B-Medical
51	22	disease	NN	O	I-NP	I-Medical
51	23	COMMA	COMMA	O	O	O
51	24	which	WDT	O	B-NP	O
51	25	is	VBZ	O	B-VP	O
51	26	the	DT	O	B-NP	O
51	27	leading	VBG	O	I-NP	O
51	28	killer	NN	O	I-NP	O
51	29	of	IN	O	B-PP	O
51	30	womenCOMMA	NN	O	B-NP	O
51	31	''	''	O	O	O
51	32	said	VBD	O	B-VP	O
51	33	Phyllis	NNP	O	B-NP	B-Peop
51	34	Greenberger	NNP	O	I-NP	I-Peop
51	35	COMMA	COMMA	O	O	O
51	36	executive	JJ	O	B-NP	B-ProfTitle
51	37	director	NN	O	I-NP	B-ProfTitle
51	38	of	IN	O	B-PP	O
51	39	the	DT	O	B-NP	O
51	40	Society	NNP	O	I-NP	B-OrgCorp
51	41	for	IN	O	B-PP	O
51	42	Women	NNP	O	B-NP	O
51	43	's	POS	O	B-NP	O
51	44	Health	NNP	O	I-NP	O
51	45	Research	NNP	O	I-NP	B-OrgCorp
51	46	.	.	O	O	O

52	0	``	``	O	O	O
52	1	We	PRP	O	B-NP	O
52	2	don	VB	O	B-VP	O
52	3	't	NN	O	B-NP	O
52	4	want	VBP	O	B-VP	O
52	5	to	TO	O	I-VP	O
52	6	take	VB	O	I-VP	O
52	7	away	RB	O	O	O
52	8	from	IN	O	B-PP	O
52	9	those	DT	O	B-NP	O
52	10	efforts	NNS	O	I-NP	O
52	11	COMMA	COMMA	O	O	O
52	12	but	CC	O	O	O
52	13	people	NNS	O	B-NP	O
52	14	need	VBP	O	B-VP	O
52	15	to	TO	O	I-VP	O
52	16	change	VB	O	I-VP	O
52	17	their	PP$	O	B-NP	O
52	18	thinking	NN	O	I-NP	O
52	19	.	.	O	O	O
52	20	''	''	O	O	O

53	0	The	DT	O	B-NP	O
53	1	Society	NNP	O	I-NP	B-OrgCorp
53	2	for	IN	O	B-PP	I-OrgCorp
53	3	Women	NNP	O	B-NP	I-OrgCorp
53	4	's	POS	O	B-NP	I-OrgCorp
53	5	Health	NNP	O	I-NP	I-OrgCorp
53	6	Research	NNP	O	I-NP	I-OrgCorp
53	7	has	VBZ	O	B-VP	O
53	8	been	VBN	O	I-VP	O
53	9	promoting	VBG	O	I-VP	O
53	10	women	NNS	O	B-NP	O
53	11	's	POS	O	B-NP	O
53	12	participation	NN	O	I-NP	O
53	13	in	IN	O	B-PP	O
53	14	health	NN	O	B-NP	O
53	15	research	NN	O	I-NP	O
53	16	since	IN	O	B-PP	O
53	17	1990	CD	O	B-NP	B-Date
53	18	.	.	O	O	O

54	0	It	PRP	O	B-NP	O
54	1	has	VBZ	O	B-VP	O
54	2	a	DT	O	B-NP	O
54	3	Web	NNP	O	I-NP	O
54	4	site	NN	O	I-NP	O
54	5	COMMA	COMMA	O	O	O
54	6	www.womancando.org	NN	O	B-NP	O
54	7	COMMA	COMMA	O	O	O
54	8	which	WDT	O	B-NP	O
54	9	is	VBZ	O	B-VP	O
54	10	a	DT	O	B-NP	O
54	11	clearinghouse	NN	O	I-NP	O
54	12	for	IN	O	B-PP	O
54	13	research	NN	O	B-NP	O
54	14	and	CC	O	I-NP	O
54	15	trial	NN	O	I-NP	O
54	16	information	NN	O	I-NP	O
54	17	.	.	O	O	O

55	0	Palmeri	NNP	O	B-NP	B-Peop
55	1	said	VBD	O	B-VP	O
55	2	the	DT	O	B-NP	O
55	3	increased	VBN	O	I-NP	O
55	4	participation	NN	O	I-NP	O
55	5	of	IN	O	B-PP	O
55	6	women	NNS	O	B-NP	O
55	7	in	IN	O	B-PP	O
55	8	medical	JJ	O	B-NP	O
55	9	research	NN	O	I-NP	O
55	10	is	VBZ	O	B-VP	O
55	11	a	DT	O	B-NP	O
55	12	step	NN	O	I-NP	O
55	13	in	IN	O	B-PP	O
55	14	the	DT	O	B-NP	O
55	15	right	NN	O	I-NP	O
55	16	direction	NN	O	I-NP	O
55	17	.	.	O	O	O

56	0	``	``	O	O	O
56	1	The	DT	O	B-NP	O
56	2	only	JJ	O	I-NP	O
56	3	way	NN	O	I-NP	O
56	4	we	PRP	O	B-NP	O
56	5	move	VBP	O	B-VP	O
56	6	forward	RB	O	O	O
56	7	is	VBZ	O	B-VP	O
56	8	by	IN	O	B-PP	O
56	9	making	VBG	O	B-VP	O
56	10	tiny	JJ	O	B-NP	O
56	11	steps	NNS	O	I-NP	O
56	12	in	IN	O	B-PP	O
56	13	the	DT	O	B-NP	O
56	14	right	NN	O	I-NP	O
56	15	directionCOMMA	NN	O	I-NP	O
56	16	''	''	O	O	O
56	17	he	PRP	O	B-NP	O
56	18	said	VBD	O	B-VP	O
56	19	.	.	O	O	O

57	0	``	``	O	O	O
57	1	Clinical	NNP	O	B-NP	O
57	2	trials	NNS	O	I-NP	O
57	3	not	RB	O	O	O
57	4	only	RB	O	O	O
57	5	have	VBP	O	B-VP	O
57	6	potential	JJ	O	B-NP	O
57	7	benefits	NNS	O	I-NP	O
57	8	for	IN	O	B-PP	O
57	9	the	DT	O	B-NP	O
57	10	population	NN	O	I-NP	O
57	11	now	RB	O	O	O
57	12	COMMA	COMMA	O	O	O
57	13	but	CC	O	O	O
57	14	also	RB	O	O	O
57	15	for	IN	O	B-PP	O
57	16	their	PP$	O	B-NP	O
57	17	friends	NNS	O	I-NP	O
57	18	COMMA	COMMA	O	O	O
57	19	children	NNS	O	B-NP	O
57	20	and	CC	O	I-NP	O
57	21	grandchildren	NNS	O	I-NP	O
57	22	.	.	O	O	O

58	0	If	IN	O	O	O
58	1	clinical	JJ	O	B-NP	B-Medical
58	2	trials	NNS	O	I-NP	O
58	3	include	VBP	O	B-VP	O
58	4	regular	JJ	O	B-NP	O
58	5	analysis	NN	O	I-NP	B-Medical
58	6	of	IN	O	B-PP	O
58	7	gender	NN	O	B-NP	O
58	8	and	CC	O	I-NP	O
58	9	ethnicity	NN	O	I-NP	B-LangRace
58	10	COMMA	COMMA	O	O	O
58	11	they	PRP	O	B-NP	O
58	12	will	MD	O	B-VP	O
58	13	become	VB	O	I-VP	O
58	14	much	RB	O	O	O
58	15	more	RBR	O	O	O
58	16	sophisticated	JJ	O	O	O
58	17	and	CC	O	O	O
58	18	much	JJ	O	O	O
58	19	more	RBR	O	O	O
58	20	expansive	JJ	O	O	O
58	21	.	.	O	O	O

59	0	As	IN	O	B-PP	O
59	1	a	DT	O	B-NP	O
59	2	consequence	NN	O	I-NP	O
59	3	COMMA	COMMA	O	O	O
59	4	the	DT	O	B-NP	O
59	5	rewards	NNS	O	I-NP	O
59	6	will	MD	O	B-VP	O
59	7	be	VB	O	I-VP	O
59	8	much	RB	O	O	O
59	9	greater	JJR	O	O	O
59	10	.	.	O	O	O
59	11	''	''	O	O	O

60	0	JL	NNP	O	O	B-Org
60	1	END	NNP	O	O	I-Org
60	2	PERRY	NNP	O	O	I-Org

61	0	-LBR-	-LBR-	O	O	O
61	1	Claudia	NNP	O	B-NP	B-Peop
61	2	Perry	NNP	O	I-NP	I-Peop
61	3	is	VBZ	O	B-VP	O
61	4	a	DT	O	B-NP	O
61	5	staff	NN	O	I-NP	O
61	6	writer	NN	O	I-NP	B-ProfTitle
61	7	for	IN	O	B-PP	O
61	8	The	DT	O	B-NP	O
61	9	Star-Ledger	NNP	O	I-NP	B-Org
61	10	of	IN	O	B-PP	O
61	11	Newark	NNP	O	B-NP	B-LocCit
61	12	COMMA	COMMA	O	O	O
61	13	N.J	NNP	O	B-NP	B-Loc
61	14	.	.	O	O	O
61	15	-RBR-	-RBR-	O	O	O
